Eris Lifesciences has received approval for acquisition of 30% of the total share capital of Swiss Parenterals, a subsidiary of the company. With the objective of fully consolidating its position, enhancing operational synergy, and strengthening its long-term strategic presence, the company now proposes to acquire 100% ownership of Swiss. This consolidation is expected to provide complete managerial control, enable full financial consolidation, improve cost efficiencies, streamline governance, and contribute to enhanced shareholder value.
The proposed transaction is expected to complete tentatively prior to March 31, 2026. The Board of Directors of the company, in their meeting held on November 24, 2025, has approved the same.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: